Clinical trials: Tislelizumab
NSCLC
MRD-guided Adjuvant Tislelizumab and Chemotherapy in Resected Stage IIA-IIIB NSCLC
Seagull is a phase Ⅱ study designed to investigate the efficacy and safety of MRD-guided adjuvant tislelizumab and chemotherapy vs adjuvant tislelizumab and chemotherapy in patients with resectable NSCLC
- Trial name
- Seagull (NCT05286957)
- Testing
- adjuvant tislelizumab and chemotherapy for MRD+ patients, adjuvant chemotherapy for MRD- patients
- Where
- China
- Volunteers
- 60 people
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
NSCLC, Tislelizumab
Tislelizumab Combined With Anlotinib and Nab-paclitaxel in II-III Resectable Non-small Cell Lung Cancer : A Prospective, Single-Arm, Phase II Study
This study is a single-arm prospective clinical trial. The primary objective of the study is to explore the efficacy and safety of preoperative neoadjuvant therapy with Tislelizumab combined with Anlotinib and Nab-Paclitaxel in…
- Conditions
- NSCLC, Tislelizumab, Anlotinib, Nab-paclitaxel
- Trial name
- TitAN (NCT07089199)
- Testing
- neoadjuvant therapy, Surgery, Adjuvant therapy
- Where
- China
- Volunteers
- 34 people
- Sponsor
- Qilu Hospital of Shandong University
RAS Mutation, Advanced Solid Tumor
A First-in-Human Study Investigating BG-85738 Alone or in Combination With Other Antitumor Agents in Patients With Advanced or Metastatic Solid Tumors With Rat Sarcoma Virus (RAS) Mutations
The purpose of this study is to test if the BG-85738 is safe and if it works in patients with advanced solid tumors with RAS mutations when it is given on its own and in combination.
- Conditions
- RAS Mutation, Advanced Solid Tumor, Metastatic Solid Tumor
- Trial name
- NCT07746141
- Testing
- BG-85738, Tislelizumab, Cetuximab
- Where
- 3 sites in Australia, New Zealand
- Volunteers
- 100 people
- Sponsor
- BeOne Medicines
Hepatocellular Carcinoma (HCC)
Tislelizumab Combined With Huaier Granule as First-line Treatment for Unresectable Hepatocellular Carcinoma
This study is a single-arm prospective clinical trial that enrolled 94 patients with unresectable hepatocellular carcinoma(HCC) who received first-line treatment with tislelizumab combined with Huaier granule.
- Trial name
- NCT07413354
- Testing
- Tislelizumab plus Huaier granule
- Where
- China
- Volunteers
- 94 people
- Sponsor
- Tongji Hospital
Colorectal Cancer
Tislelizumab in People With Colorectal Cancer
The researchers are doing this study to find out whether tislelizumab is an effective treatment for people with colorectal cancer who are living in Nigeria. The researchers will also look at the safety of the study drug.
- Trial name
- NCT06529523
- Testing
- Tislelizumab
- Where
- 3 sites in United States, Nigeria
- Volunteers
- 40 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Esophageal Squamous Cell Carcinoma (ESCC)
Early Response-guided Sequential Radiotherapy After Chemoimmunotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma
Esophageal squamous cell carcinoma (ESCC) is a common and aggressive malignancy with poor prognosis, particularly in patients with locally advanced disease.
- Trial name
- Keystone006 (NCT07721103)
- Testing
- Neoadjuvant Chemoimmunotherapy (Tislelizumab Plus Paclitaxel and Cisplatin), Sequential Chemoradiotherapy
- Where
- China
- Volunteers
- 110 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Advanced Solid Tumor, Metastatic Solid Tumor
BGB-A3055 Alone and in Combination With Tislelizumab in Participants With Solid Tumors
This study aims to evaluate how safe and well-tolerated the treatment is, how the body processes it, how it works on the tumors, and whether it shows early signs of fighting cancer in people with certain advanced or metastatic…
- Conditions
- Advanced Solid Tumor, Metastatic Solid Tumor, Solid Tumor
- Trial name
- NCT05935098
- Testing
- BGB-A3055, Tislelizumab, Chemotherapy
- Where
- 26 sites in United States, Australia and 3 more
- Volunteers
- 99 people
- Sponsor
- BeiGene
Carcinoma, Hepatocellular
Cryoablation Combined With PD-1 Antibody and Bevacizumab for Hepatocellular Carcinoma
To explore the safety and efficacy of cryoablation combined with PD-1 antibody and bevacizumab for patients with hepatocellular carcinoma resistance to PD-1/L1 antibody.
- Trial name
- NCT06530784
- Testing
- Cryoablation, PD-1 antibody and bevacizumab
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Shanghai Zhongshan Hospital
Lymphoma, Large B-Cell, Diffuse, Transplantation
PD-1 Inhibitor Tislelizumab Maintenance Therapy in Newly Diagnosed DLBCL Patients After ASCT
This is a multicenter, randomized controlled, prospective clinical trial. The objective is to investigate the efficacy and safety of Tislelizumab maintenance therapy in newly diagnosed diffuse large B-cell lymphoma (DLBCL)…
- Conditions
- Lymphoma, Large B-Cell, Diffuse, Transplantation, Chemotherapy
- Trial name
- NCT04789434
- Testing
- PD-1 Inhibitor Tislelizumab maintenance therapy
- Where
- China
- Volunteers
- 94 people
- Sponsor
- Ruijin Hospital
Resectable Esophageal Squamous Cell Carcinoma
Study of Tislelizumab in Participants With Resectable Esophageal Squamous Cell Carcinoma
The purpose of this study is to evaluate the pathological complete response (pCR) in participants receiving tislelizumab plus chemotherapy/chemoradiotherapy as neoadjuvant treatment.
- Trial name
- RATIONALE-213 (NCT04974047)
- Testing
- Tislelizumab, Paclitaxel, Cisplatin
- Where
- 8 sites in China
- Volunteers
- 70 people
- Sponsor
- BeiGene
Advanced Malignancies
Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies
This is an open-label, multicenter, extension study to evaluate the long-term safety and efficacy of BeiGene or BeOne investigational drugs in participants with advanced malignancies who participated in a prior BeiGene- or…
- Trial name
- NCT04164199
- Testing
- Tislelizumab, Pamiparib, Temozolomide
- Where
- 106 sites in United States, Australia and 11 more
- Volunteers
- 404 people
- Sponsor
- BeOne Medicines
Extensive-stage Small Cell Lung Cancer (ES-SCLC)
Tislelizumab Combined With Chemotherapy and Relayed Radiotherapy in First-line Treatment of ES-SCLC
To explore the efficacy and safety of Tislelizumab combined with chemotherapy and relayed radiotherapy in the first-line treatment of extensive small cell lung cancer
- Trial name
- NCT06838208
- Testing
- Tislelizumab, Carboplatin /Cisplatin, Etoposide
- Where
- China
- Volunteers
- 56 people
- Sponsor
- Anhui Provincial Cancer Hospital
Triple-negative Breast Cancer
A Phase Ⅱ Study of Anlotinib Combined With Tislelizumab and AT in the Neoadjuvant Treatment of Triple-negative Breast Cancer
This is a prospective, single-arm and open-label phase II study, evaluating the efficacy and safety of anlotinib combined with tislelizumab and AT regimen as neoadjuvant treatment for triple-negative breast cancer.
- Trial name
- NeoATCT (NCT04914390)
- Testing
- AT regimen, Tislelizumab, Anlotinib
- Where
- China
- Volunteers
- 32 people
- Sponsor
- Sichuan Provincial People's Hospital
Lynch Syndrome, Recurrent Endometrial Carcinoma
Tislelizumab for the Treatment of Recurrent Mismatch Repair Deficient Endometrial Cancer
This clinical trial evaluates the effect of tislelizumab in treating patients with mismatch repair deficient endometrial cancer that has come back (recurrent).
- Conditions
- Lynch Syndrome, Recurrent Endometrial Carcinoma, Recurrent Endometrial Clear Cell Adenocarcinoma, Recurrent Uterine Corpus Carcinosarcoma
- Trial name
- NCT04906382
- Testing
- Biopsy, Carboplatin, Paclitaxel
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Floor Backes, MD
Tongue Squamous Cell Carcinoma
Lingual Nerve Disruption to Augment Neoadjuvant Chemoimmunotherapy in Locally Advanced Tongue Cancer
The goal of this clinical trial is to evaluate the feasibility and preliminary efficacy of lingual nerve disruption combined with neoadjuvant chemoimmunotherapy in patients with locally advanced tongue squamous cell carcinoma.
- Trial name
- NCT07346807
- Testing
- Lingual Nerve Disruption, Tislelizumab, Albumin-bound Paclitaxel
- Where
- China
- Volunteers
- 69 people
- Sponsor
- Shanghai Zhongshan Hospital
Advanced Gastric Cancer, Advanced Gastroesophageal Junction Adenocarcinoma
Tislelizumab Combined With S-1 Plus Oxaliplatin as a Neoadjuvant Treatment in Patients With GC/GEJC
At present, the treatment of advanced gastric/gastroesophageal junction cancer is a research hotspot in the academic community. In Asia, Siewert type II and type III are the main types of advanced gastric/gastroesophageal…
- Trial name
- NCT04890392
- Testing
- PD-1 inhibitor(Tislelizumab) ,SOX(S-1+ Oxaliplatin)
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Advanced or Metastatic Non-small Cell Lung Cancer
Phase III Study of SHR-8068 Combined With Adebrelimab and Chemotherapy Versus Tislelizumab Combined With Chemotherapy in the Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer
This study is a randomized, open-label, controlled, multicenter Phase III clinical trial to evaluate the efficacy and safety of SHR-8068 combined with adebrelimab and platinum-based chemotherapy versus tislelizumab combined with…
- Trial name
- NCT07170995
- Testing
- SHR-8068，adebelizumab and platinum-based chemotherapy, tislelizumab, and platinum-based chemotherapy
- Where
- China
- Volunteers
- 460 people
- Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Lung Carcinoma
A Study of SKB518 in Patients With Lung Cancer
This is an open-label, multicenter, phase II study. The purpose of this study is to evaluate the safety, tolerability and preliminary anti-tumor activity of SKB518 in patients with lung cancer.
- Trial name
- NCT07019675
- Testing
- SKB518, Tislelizumab, Carboplatin
- Where
- 17 sites in China
- Volunteers
- 192 people
- Sponsor
- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Non-small Cell Lung Cancer
The Impact of Thymosin α-1 on the Efficacy of Concurrent Chemoradiotherapy Followed by Immunotherpay Consolidation for Locally Advanced NSCLC
This prospective phase II randomized study is to determine the impact of thymosin alpha-1 on the concurrent chemoradiotherpay followed by immunotherapy consolidation in patients with locally advanced NSCLC by assessing the…
- Trial name
- NCT06139419
- Testing
- definitive radiotherapy, induction chemo-immunotherapy, concurrent chemotherapy
- Where
- China
- Volunteers
- 114 people
- Sponsor
- Sun Yat-sen University
Advanced Solid Tumor
A Dose Escalation and Dose Expansion Clinical Study of STI-7349 in Subjects With Advanced Solid Tumors
This is a first-in-human, Phase Ⅰ, open-label, 2-period dose escalation and expansion study of STI-7349 administered intravenously to subjects with advanced solid tumors: Period I is divided into two parts: Dose escalation for…
- Trial name
- NCT05978102
- Testing
- STI-7349, Pembrolizumab, Standard treatment（SoC）
- Where
- China
- Volunteers
- 183 people
- Sponsor
- The Fourth Affiliated Hospital of Zhejiang University School of Medicine